COVID-19 has upended virtually every aspect of healthcare, including medical education. As the novel coronavirus expanded from a crisis to a pandemic, medical students adjusted to online learning from home. Residents and fellows were told to avoid direct patient care, got pulled into ERs and ICUs to treat COVID-19 patients, or saw clinical rotations canceled altogether.
Encouraging results were published today, September 2, in JAMA reporting on the reduction in 28-day mortality associated with steroid administration in critically ill COVID-19 patients. The authors reported on their prospective meta-analysis of 7 randomized trials, with a total of 1703 patients, who were randomized to either corticosteroids or placebo (or usual care). There were
In addition to managing the enormous burden of COVID-19 infection and mortality, clinicians are also charged with how we can best provide ongoing regular care for non-COVID patients.
In a special report last week, the European Heart Journal spoke to cardiovascular disease (CVD) thought leaders across the globe to gather their insights on the impact of the COVID-19 pandemic on cardiovascular care.
Various healthcare organizations are working to better prepare physicians and advanced practice providers for best practices in providing virtual care.
The pandemic has accelerated the pace of positive change, exposed longstanding racial inequalities that resulted in a disproportionate burden of COVID-19 infection and mortality, and demonstrated new learning needs for health care professionals.
THE RECOVERY TRIAL News emerged from the UK on June 16 around very promising results with dexamethasone in the treatment of COVID-19 infected patients in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial. RECOVERY is a randomized trial investigating whether treatment with either (1)Lopinavir-Ritonavir, (2)Hydroxychloroquine, (3)Corticosteroids, (4)Azithromycin,(5) Convalescent plasma or (6)Tocilizumab prevents death in patients with COVID-19.
A group of Italian researchers recently hypothesized that it is actually the endothelium that is being targeted by the COVID-19 virus.
It was initially thought that perhaps children, when infected with COVID-19, developed milder cases which appear clinically like a minor upper respiratory infection. In late April, however, the first published case of a Kawasaki-like disease associated with COVID-19 was described in Hospital Pediatrics.
To date, several pharmaceutical agents have been evaluated in the treatment of COVID-19. On May 23, the first report of a positive response to a therapeutic agent, remdesivir, was reported in the New England Journal of Medicine. The positive top line results of this trial were shared via a press release a few weeks ago.